Top 5 Cannabis VC (Venture Capital) Funds in United Kingdom in July 2025

Last updated: Jul 2025 A list of 5 VC (Venture Capital) funds that invest in Cannabis startups based in United kingdom. We rank investors based on the number of investments they made in Cannabis companies from United kingdom. We update this investor list every month.

Top 5 Cannabis VC (Venture Capital) Funds in United Kingdom in July 2025

Investor	Cannabis United Kingdom investments
Kindred Capital	1
Deepbridge Capital	1
Measure 8 Venture Partners	1
Casa Verde Capital	1
Leafy Tunnel	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

A new model for Venture Capital where every founder we back becomes a co-owner of the fund

Investment focus

Software, Biotechnology, Information Technology
Seed, Series A, Series B
United Kingdom, United States, Germany

Portfolio highlights

Cakewalk — Cakewalk enables IT & Security teams to monitor all SaaS apps used by their employees, run compliant access flows, securely on- and offboard people, and be IT audit-ready.
Latent Labs — Latent Labs is making biology programmable to transform health and sustainability for the benefit of all.We are a frontier AI lab building foundational models that capture the fundamentals of biology. We empower partners with breakthrough generative AI to gain unprecedented control over molecular biology, creating new antibodies, optimizingexisting enzymes, and advancing genetic engineering.Contact us to work with us today.
Sohar Health — Streamline patient intake and boost revenue with Sohar's real-time insurance verification and eligibility solutions. Automate workflows, reduce claim denials, and improve conversion rates with accurate, fast, and reliable tools. Book a demo today to transform your patient onboarding process.

Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Australia, Singapore

Portfolio highlights

AI-Sight — AI-Sight is a startup that is developing an AI diabetic retinal screening system to deliver WHO-recommended diabetic eye screening services.
Microplate Dx — Safeguarding against the spread of antimicrobial resistance worldwide.
GenoMe Diagnostics — GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .

Measure 8 Venture Partners, LP is an alternative investment vehicle created to capitalize on the emergence of the U.S. and global cannabis industry.

Investment focus

Cannabis, Alternative Medicine, Health Care
Funding Round, Seed, Convertible Note
United States, Germany, United Kingdom

Portfolio highlights

Neatleaf — Sustainable agriculture with optimal yields through data-driven understanding and comprehensive automation for everyone.
EMMAC Life Sciences — EMMAC is a medical cannabis company that works to join together the latest science and research with cutting-edge cultivation, extraction, and production. It has developed unique supply and distribution partnerships across Europe to establish itself not only as a thought leader at the very forefront of research into the medical benefits of cannabisbut also as a European leader in the production and supply of medical cannabis, hemp, and other derivatives products.It was founded in 2018 and is headquartered in London, England.
Bloomwell Group — The Bloomwell Group provides easy access to natural-based medicine and with a patient-centric D2C approach, it mainly focuses on a strong and revolutionizing streamlined customer journey. Bloomwell Group is focusing on the treatment of chronic diseases with significantly fewer side effects than conventional medicine.

As both the domestic and international markets continue to evolve and mature, Casa Verde maintains a view that cannabis will be among the most compelling investment themes of our generation.